A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs VPI 2690B (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors Vascular Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Dec 2015 Number of treatment arms changed from 3 to 4, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top